Sativex® approved in Sweden for the treatment of spasticity due to Multiple Sclerosis (MS)
22 December 2011
GW Director Wins Wellcome Medal
12 December 2011
GW files new regulatory application to expand Sativex® approvals to additional European countries
22 November 2011
2011 Preliminary Results
22 November 2011
European patent granted for Sativex® formulation
17 November 2011
Phase III data on efficacy and tolerability of Sativex® in MS spasticity presented at ECTRIMS
24 October 2011
Sativex Launched in Denmark
18 July 2011
Sativex launched in Germany
4 July 2011
Second phase III Sativex® cancer pain trial commences
30 June 2011
Sativex® approved in Denmark for the treatment of spasticity due to Multiple Sclerosis (MS)
8 June 2011
Sativex® approved in Germany for the treatment of spasticity due to Multiple Sclerosis
26 May 2011
Interim Results Show Strong Revenue Growth, Profit and Increased Cash Position
17 May 2011
US Patent Granted for Sativex in Cancer Pain
20 April 2011
Sativex® Approved in the Czech Republic
15 April 2011
GW Signs Exclusive Licence Agreement to Commercialise Sativex in Australia, Asia, Middle-East and Africa
11 April 2011
Sativex Mutual Recognition Procedure Closes with Recommendation for Approval in all Six European Countries Involved
22 March 2011
Sativex® launched in Spain to treat spasticity
14 March 2011
Sativex® improves symptoms of spasticity due to MS, study shows
2 March 2011
Sativex granted reimbursement in Spain
17 February 2011
Receipt of Milestone Payment
17 January 2011
